5AM Ventures’ Post

We have reached a major milestone, dosing the first patients in our Phase 2 RESOLVE-1 #ClinicalTrial, investigating the therapeutic potential of NT-0796, our oral #NLRP3 #inflammasome inhibitor, in patients with #obesity. Our earlier research has demonstrated that NLRP3, a master switch of #inflammation, plays a key role in controlling obesity and obesity-associated inflammation. NT-0796 is designed to target chronic inflammation at its source and address the complex biology of weight regulation, aiming to restore metabolic balance and enable sustained, healthy weight loss. Following our recently closed $50 million Series D financing, we’re excited to accelerate this lead program through a robust Phase 2 trial. Learn more here: https://lnkd.in/e5yu6amC #Biotech #NodThera #Innovation #Data